Martin, Diana

Papers in refereed journals, series or books:

• Ruijne N, Lea RA, O’Hallahan J, Oster P, Martin D. (2006) Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in infant studies. Clin Vaccine Immunol 13: 797-801 (CVI00038-06).
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D., Zollinger W, J Robbins, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman  J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D. (2006) Neisseria meningitidis Group B Correlates of Protection and Assay Standardization - International Meeting Report Emory University, Atlanta Georgia United States, (16-17 March 2005.JVAC-D-06-00312) Vaccine 24:5093-5107.
• Martin DR, Ruijne N, McCallum L, O’Hallahan J, Oster P. (2006) The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 13: 486-491.
• Dyet K, Martin D. (2006) Clonal analysis of the serogroup B meningococci causing New Zealand’s epidemic. Epidemiol Infect. 134, 377-383.
• Thornton V, Lennon D, Rasanathan K, O’Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nokelby H, Rosenqvist E, White K, Reis S, Mulholland K, Wakefield MJ, Martin D.  (2006) Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control. Vaccine 24:1395-1400.
• Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, Findlow J, Hoiby A, Rosenqvist E, Balmer P, Martin D. (2005) Interlaboratory standardizatioon of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesivle vaccine. Clin Diag Lab Immunol 12: 970-976 
• Yang L, Thomas M, Woodhouse A, Martin D, Fraser J, Proft T. (2005)  Involvement of streptococcal mitogenic exotoxin Z (SMEZ) in streptococcal toxic shock syndrome – A case study.  J Clin Microbiol; 43: 3570-3573.
• Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZBTM : a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23: 2199-2204.
• O'Hallahan J, Lennon D, Oster P, Reid S, Mulholland K, Martin D. From secondary prevention to primary prevention - a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 2005; 23: 2205-2209.
• Martin D, McCallum L, Glennie A, Ruijne N, Blatchford P, O'Hallahan J, Oster P. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine 2005; 23: 2226-9.
• Dyet K, Devoy A, McDowell R, Martin D. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 2005; 23: 2236-38.
• Dyet K, Martin D. Sequence variation in the porB gene from B:P1.7-2,4 meningococci causing New Zealand's epidemic. J Clin Microbiol 2005; 43: 838-842.
• Devoy AF, Dyet KH, Martin DR. Stability of PorA during a meningococcal disease epidemic. J Clin Microbiol 2005; 43: 832-837.
• Dyet KH, Simmonds RS, Martin DR. Multilocus restriction typing method to predict the sequence type of meningococci. J Clin Microbiol 2004; 42: 1742-1745.
• Dyet KH, Simmonds RS, Martin DR. Evaluation of porB-PCR amplicon restriction endonuclease analysis as a method to determine porB variable-region sequences in nonserotypable meningococci. J Clin Microbiol 2004; 42: 1731-1733.
• Sexton K, Lennon D, Oster P, Crengle S, Martin D, Mulholland K, Percival T, Reid S, Stewart J, O'Hallahan J. The New Zealand meningococcal vaccine strategy: A tailor made vaccine to combat a devastating epidemic. NZMJ 2004; 117. URL:http://www.nzma.org.nz/journal/117-1200/1015
• Wilson N, Wenger J, Mansoor O, Baker M, Martin D. The beneficial impact of Hib vaccine on disease rates in New Zealand children. NZ Med J 2002; 115: 1-7.
• Kong F, Martin D, James G, Gilbert GL. Towards a genotyping system for Streptococcus agalactiae (group B streptococcus): use of mobile genetic elements in Australasian invasive isolates. J Med Microbiol 2003; 52: 337-44.
• Holst J, Aaberge IS, Oster P, Lennon D, Martin D, O'Hallahan J, et al. A 'tailor made' vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Eurosurveillance Weekly 2003; 7: 6-9.
• Wichtel MEG, Hunter JEB, Fenwick SG, Stephenson A, Martin D. Lactococcus lactis as a cause of septic arthritis and septicaemia in a neonatal calf. Vet. Record 2003; 153: 22-23.
• Facklam RF, Martin DR, Lovgren M, Johnson DR, Efstratiou A, Thompson RA, Gowan S, Kriz P, Tyrrell GJ, Kaplan E, Beall B. Extension of the Lancefield classification for Group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm 124. Clin Infect Dis 2002; 34: 28-38.
• Kong F, Gowan S, Martin D, James G, Gilbert GL. Serotype identification of group B streptococci (GBS) with PCR and sequencing. J Clin Microbiol 2002;4- 620-6.
• Kong F, Gowan S, Martin D, James G, Gilbert GL. Molecular profiles of group B streptococci (GBS) surface protein antigen genes - relationship to molecular serotypes. J Clin Microbiol 2002;40: 216-26.
• Grimwood K, Stone PR, Gosling IA, Green R, Darlow BA, Lennon DR, Martin DR. Late antenatal carriage of group B streptococcus by New Zealand women. Aust NZ J Obstet Gynaecol 2002; 42: 217-221.
• Grimwood K, Darlow BA, Gosling IA, Green R, Lennon DR, Martin DR, Stone PR. Early onset neonatal group B streptococcal infections in New Zealand 1998-1999. J Paediatr Child Health 2002; 38: 272-7.
• Simmons G, Martin D, Stewart J, Jones N, Calder L, Bremner D. Carriage of Neisseria meningitidis among household contacts of patients with meningococcal disease in New Zealand. Eur J Clin Microbiol Infect Dis 2001; 20: 237-42.
• Baker M, Martin DR, Kieft CEM, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand : descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001;37: S13-S19.
• Proft T, Moffatt SL, Weller KD, Paterson A, Martin D, Fraser JD. The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation. J Exp Med 2000; 191: 1765-6.
• Simmons G, Martin D, Stewart J, Bremner D. Carriage of N. lactamica in a population at high risk of meningococcal disease. Epidemiol Infect 2000; 125: 99-104.

Conference papers and abstracts:

• Lennon D, Martin D, Stewart J, Farrell E, Palmer A, Mason H. Re-evaluation of a school-based primary preventioned acute rheumatic fever (ARF) randomised controlled trial (RCT): poised for action. XVI Lancefield International Symposium on streptococci and streptococcal diseases. Palm Cove, Australia, 25-29 September 2005.
• Yang L, Woodhouse A, Martin D, Fraser JD, Proft T.  Involvement of superantigens in streptococcal toxic shock syndrome – a case control study. Lancefield International Symposium on streptococci and streptococcal diseases. Palm Cove, Australia, 25 29 September 2005.
• Martin D. The epidemiology of meningococcal disease in New Zealand, 2004. Poster presentation at the European Monitoring Group Meeting on Meningococci, Dublin, 7 9 September 2005.
• Martin D. The epidemiology of New Zealand’s epidemic, immune responses to and the rollout of the MeNZBTM vaccine. Oral presentation. The European Monitoring Group Meeting on Meningococci 2005, Dublin, 7-9 September 2005.
• Martin D. Laboratory acquired meningococcal disease or coincidental infection? Oral presentation. The European Monitoring Group Meeting on Meningococci 2005, Dublin, 7 9 September 2005.
• Davies H, Kay D, McDowell R, Lopez L, Ngatai M, Martin D. The epidemiology of meningococcal disease in New Zealand, 2004. New Zealand Institute of Medical Laboratory Science, 16-18 August 2005.
• Martin D, Oster P, O’Hallahan J. From bean counting to control of an epidemic in 15 years: New Zealand’s meningococcal disease story. Tri-State Meeting, Darwin, Australia, 8-9 July, 2005
• Sexton K, Lennon D, Oster P, Aaberge I, Martin D, Reid S, Wong S, O'Hallahan J Proceedings of the Meningococcal Vaccine A strategy World Health Organisation Satellite Meeting, 10 March 2004, Auckland, New Zealand. NZ Med J 2004; 117-1200/1026/.